Rocatinlimab is an OX40 agonist for the treatment of moderate to severe atopic dermatitis (AD) and is currently undergoing a multicenter, double-blind maintenance study of long-term safety, tolerability and efficacy in adult and adolescent subjects. This evidence concerns the gene TNFRSF4 and Alzheimer disease.